Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Name

Click to order products ascending

Display 15 Products per page

Aggrenox
Read More
Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole.
July 2, 2018
Find out more
AGS-003
Read More
AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).
February 5, 2016
Find out more
Alecensa
Read More
lecensa is a second-generation ALK inhibitor developed by Roche and Chugai. In some NSCLC

patients, abnormal ALK configuration leads to the production of proteins that promote and maintain

the malignant behavior of cancer cells (Soda et al., 2008).
August 30, 2018
Find out more
Alimta
Read More
Alimta is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication.
August 30, 2018
Find out more
Aliqopa
Read More
Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth.
January 31, 2019
Find out more
ALKS 3831
Read More
ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.
April 9, 2018
Find out more
ALKS 5461
Read More
ALKS 5461 (Alkermes) is a fixed-dose combination of buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor antagonist, and samidorphan (ALKS 33), which is a proprietary opioid modulator.
March 29, 2019
Find out more
ALKS 8700
Read More
ALKS 8700 is an oral monomethyl fumarate molecule being developed for the treatment of relapsing multiple sclerosis.
November 24, 2017
Find out more
Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Find out more
Alofisel
Read More
Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.
August 2, 2018
Find out more
Alpelisib
Read More
Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
Alprolix
Read More
Biogen and Swedish Orphan Biovitrum co-developed Alprolix (recombinant factor IX [rfIX] Fc fusion protein) for the treatment of hemophilia B. The therapy is a recombinant protein consisting of a single fIX fused with the dimeric Fc region of immunoglobulin G-1.
May 4, 2018
Find out more
Alunbrig
Read More
Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
September 8, 2018
Find out more
Alzheimer’s Disease KOL Interview – UK

$599.00

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.
January 20, 2019
Find out more
Alzheimer’s Disease KOL Interview – US, Northeast

$599.00

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.
January 28, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *